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Group  G Streptococcus (GGS) can cause severe
infections, including bacteremia. These organisms often
express a surface protein homologous to the Strep-
tococcus pyogenes M protein. We retrospectively studied
the characteristics of patients from the Hadassah Medical
Center with GGS bacteremia from 1989 to 2000. Ninety-
four cases of GGS bacteremia were identified in 84
patients. The median age was 62 years, 54% were males,
and 92% had underlying diseases (35% had a malignancy,
and 35% had diabetes mellitus). The most frequent source
for bacteremia was cellulitis (61%). emm typing of 56 avail-
able isolates disclosed 13 different types, including 2 novel
types. Six patients had recurrent bacteremia with two to
four bacteremic episodes, five had chronic lymphatic disor-
ders, and two had emm type stG840.0 in every episode.
Recurrent bacteremia has not been described for invasive
group A Streptococcus. We describe an entity of recurrent
GGS bacteremia, which is associated with lymphatic disor-
ders and possibly with emm stG840.0. 
L
arge colony-forming group G β-hemolytic streptococ-
ci (GGS) were first isolated in patients with puerperal
sepsis in 1935 (1). GGS are known to be commensals and
pathogens in domestic animals. In humans, they may col-
onize the pharynx, skin, gastrointestinal and female genital
tract (2). In recent years, GGS have been reported with
increasing frequency as the cause of a variety of human
infections, such as pharyngitis, cellulitis, meningitis, endo-
carditis, and sepsis (2–8). Bacteremia attributable to GGS
has been related to underlying conditions, such as alco-
holism, diabetes mellitus, malignancy, intravenous sub-
stance abuse, or breakdown of the skin (2–7,9,10).
The taxonomy of these organisms has been reevaluated
in recent years. The Lancefield group G carbohydrate may
be encountered in several β-hemolytic streptococcal
species, including Streptococcus anginosus and S. canis,
but mainly in S. dysgalactiae subsp. equisimilis, which is
the subject of our study (11). This subspecies also hosts
variants with Lancefield group A, C, and L carbohydrates.
The subspecies epithet was determined by gene sequenc-
ing of the group C species previously named Streptococcus
equisimilis, which showed it to be indistinguishable from
group G S. dysgalactiae. This finding resulted in the
description of a new taxon, S. dysgalactiae subsp. equisim-
ilis. The true proportions of the non-G carbohydrates
among members of this taxon are difficult to estimate. In a
prospective, population-based study of invasive S. pyo-
genes infections (12), we found six isolates with the group
A antigen to be S. dysgalactiae subsp. equisimilis. Among
isolates from infections attributable to S. dysgalactiae
subsp. equisimilis, the group C and G antigen was found
much more commonly in human infections than group A
(GAS) (11).
S. dysgalactiae subsp.  equisimilis and  S. pyogenes
share virulence factors such as streptokinase, C5a pepti-
dase, M protein, streptolysin S, and certain exotoxin genes
(13–18). The M protein is an important virulence factor
because it confers resistance to phagocytosis (19). M pro-
teins of GAS and GGS obtained from human infections
have similar biologic, immunochemical, and structural
features (20). The substantial polymorphism exhibited by
GAS M proteins has also been described for GGS (21). We
have conducted a 12-year retrospective study to establish
the incidence, clinical features, epidemiologic characteris-
tics, and emm typing of GGS isolates that cause bacteremia
in a large tertiary-care center in Jerusalem, Israel.
Materials and Methods
A retrospective study was conducted from 1989
through 2000 at the Hadassah Hospitals, Jerusalem, Israel.
This is a 1,000-bed, tertiary-care center with all major dis-
ciplines represented, including hematology, oncology, and
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Clinical Characteristics
We reviewed the records of all patients in whom a pos-
itive blood culture of GGS was reported. Demographic and
clinical data were collected. Death rates were measured
only during hospitalization. Descriptive statistics were per-
formed with the SPSS (SPSS Inc., Chicago, IL) statistical
package release 11.01. The Fisher exact test was used for
differences in proportions. A two-sided p value of <0.05
was considered significant. 
Microbiologic Methods
Patients with GGS bacteremia were retrieved from the
microbiology laboratory database of bacteremia. No more
than one isolate per admission was included. Clinical spec-
imens were collected and handled according to standard
protocols. During the study period, the BACTEC 460
radiometric system and the BacTAlert (Organon Teknika,
Belgium) blood culture system were used. 
All catalase-negative, chain-forming, gram-positive
cocci that were β-hemolytic on 5% sheep blood agar were
Lancefield serogrouped by using kits according to the
manufacturer’s instructions (PathDox Strep Grouping,
DPC Diagnostic Products Corporation, Los Angeles, CA).
We had 56 isolates available for further analysis. These
had been stored at –70°C in the laboratory collection of
blood culture isolates. All isolates displayed large
colonies and did not belong to the S. anginosus group (“S.
milleri”).
Molecular Methods
An overnight growth was resuspended in saline and
heated at 70°C for 15 min. Bacteria were then resuspend-
ed in 50 µLof 10 mmol/LTris, 1 mmol/LEDTA, pH 8. Ten
microliters of mutanolysin (3,000 U/mL) and 2 µL
hyaluronidase (30 mg/mL) were added. After incubation at
37°C for 30 min and heat inactivation at 100°C for 10 min,
the supernatant was subjected to polymerase chain reac-
tion (PCR). Fifty-six GGS isolates were emm typed. PCR
was performed as described (http://www.cdc.gov/ncidod/
biotech/strep/doc.htm). Primers used for amplification of
GGS DNA were G1F and G1R, previously described by
Schnitzler et al. (21).
According to recommendations (http://www.cdc.gov/
ncidod/biotech/strep/doc.htm), the sequence of the sense
strand of the emm hypervariable coding region was deter-
mined by using primer 1 (5′ TATTCGCTTAGAAAAT-
TAA 3′) by automated sequencing (Hy Laboratories Ltd.,
Rehovot, Israel). The sequence of base pair numbers
30–260 was submitted by using the Streptococcal Group A
Subtyping Request Form, to the Blast 2.0 Core Facility
(http://www.cdc.gov/ncidod/biotech/strep/strepblast.htm),
where emm type was determined (22).
The 12 strains from recurrent infection were analyzed
by pulsed-field electrophoresis (PFGE). Chromosomal
DNA was digested with SmaI and prepared and analyzed
as described with minor modifications (23).
Results 
The 504 bloodstream isolates of β-hemolytic
Streptococcus from 1989 through 2000 included the fol-
lowing: 232 (46%) group A, 171 (34%) group B (GBS), 94
(19%) group G, and 7 (1.4%) groups F and C. The 94
episodes of GGS bacteremia involved 84 patients, 6 of
whom had recurrent infections. Patient characteristics are
summarized in Tables 1 and 2. The annual incidence of
GGS bacteremia was 0.0–0.2 cases/1,000 admissions dur-
ing the 12-year study; the incidence ranges for GAS and
GBS were 0.2–0.48 and 0.19–0.3, respectively (Figure 1).
Five patients died, but only two of the deaths were
directly attributed to the GGS bacteremia. The other three
deaths were related to malignancy in two patients and con-
gestive heart failure in one.
Of the 56 GGS isolates available for emm typing, we
found 13 emm types (including 2 subtypes of stG6: stG6.0
and stG6.1). These types included stG507.1, a variant of
emmLG507.0 (GenBank accession no. X79527) and
stG6792.0 (identical to a partial gene sequence, accession
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Table 1. Summary of clinical characteristic of 94 patients with 
group G streptococcal bacteremia  
Characteristic   No. of patients (%)  
Age (y)   
<10  3 (3.1) 
10–50  28 (29.8) 
51–75  42 (44.7) 
>75  21 (22.3) 
Median (range)  62 (2–92) 
Male  51 (54.2) 
Median LOH
a in days   10 
Underlying disorder    
Diabetes mellitus   33 (35.1) 
Malignancy  33 (35.1) 
Hypertension  18 (19.1) 
No disease  8 (8.5) 
Type of infection    
Cellulitis   56 (59.6) 
Primary bacteremia   18 (19.1) 
Soft-tissue infection
b  4 (4.3) 
Bone and joint   4 (4.3) 
Endocarditis  3 (3.1) 
Respiratory  3 (3.1) 
Postpartum  1 (1.1) 
Line sepsis  1 (1.1) 
Unknown  4 (4.3) 
Death rate  5 (5.3) 
aLOH, length of hospitalization.  
bSoft tissue infection, pressure sore attributable to diabetes.  no. AF485842, listed from a blood isolate of S. dysgalacti-
ae subsp. equisimilis), which were not in the database. The
patient with the stG507.1 bacteremia had cellulitis, and
two patients had the stG6792.0 strain: one was a 17-year-
old patient with venous malformations of the leg and
pelvis who had GGS sepsis and multiorgan failure, and the
other was a 92-year-old man with diabetes and cellulitis.
No association was found between emm type and year of
study, season, source of infection, or cellulitis location.
Six patients had recurrent bacteremia, ranging from 2 to
4 episodes per patient (Table 3). All six patients had a com-
munity-acquired recurrent cellulitis and were given treat-
ment similar to that received by patients who did not have
a recurrent infection. Five patients had chronic lymphatic
abnormalities at the infection site compared to 11 of 42
patients with nonrecurrent cellulitis (odds ratio [OR] 14.1,
95% confidence interval [CI] 1.5–134.3, p = 0.012). Two
patients had recurrent infection with the same emm type,
stG840.0 (one patient had three episodes, 1 and 7 months
apart; the other patient had 2 episodes, 6 months apart).
Three patients had a different emm type each episode. The
isolates of the patient with four recurrent episodes were not
available for emm typing. PFGE results indicated that iso-
lates recovered from the same patient that shared the same
emm type were highly genetically related (Figure 2). 
Discussion
GGS are widely distributed in nature and are recog-
nized as both commensals and pathogens in animals as
well as in humans. S. dysgalactiae subsp. equisimilis is
part of the normal bacterial flora in humans. S. dysgalacti-
ae subsp. equisimilis is the most common species of large
colony-forming serogroup G streptococci that is β-
hemolytic on sheep blood agar. The animal-associated S.
canis has rarely been implicated as a human pathogen,
although accurate data are not available (11,24).
Asymptomatic pharyngeal carriage of GGS has been
described in up to 23% of humans (25), and vaginal car-
riage in 5% of asymptomatic puerperal women (1). 
This 12-year retrospective survey identified 94
episodes of GGS bacteremia at the Hadassah-Hebrew
University Medical Center. It is one of the two largest
series of GGS bacteremia described in the literature to date
(26). Some similarities were found in the epidemiologic
characteristics of group G streptococcal bacteremia
between our study and other studies. Patients were pre-
dominantly elderly men. Most patients (92%) had underly-
ing diseases, similar to those (74%–92%) reported
previously (2–6,9).
As shown by Auckenthaler et al. (3) and Woo et al. (6),
malignancy was one of the most important underlying con-
ditions associated with GGS bacteremia, affecting 35% of
our patients. In our patients, the most common malignan-
cy associated with cellulitis was carcinoma of the breast.
The most common source of infection among patients with
bacteremia with a known source was soft tissue infection,
especially cellulitis (61%), 66% of these infections were
confined to the lower limbs. Similarly, 48% of our patients
with cellulitis had an underlying skin lesion; in 35% of the
patients, it was related to lymphatic abnormalities. These
abnormalities were mostly attributed to malignancy, sur-
gery, or radiation. Two patients had a congenital lymphat-
ic malformation. 
Nineteen percent of our patients had primary bac-
teremia, which is within the range (11%–52%) described
by others (2,3,6,7). The death rate in our study (5%) was
lower than that previously reported (8%–30%) (3,6,9).
One reason for this finding may be the relatively younger
age of our patients: Only 22% of our patients were >75
years of age compared to those from Sylvetsky’s group,
where 63% were >75 years of age (9). The small number
of patients who eventually died of bacteremia precluded
analysis of risk factors associated with death.
In contrast to the previous study from a different hospi-
tal in Jerusalem, Israel, describing GGS bacteremia during
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Table 2. emm types of 94 patients with group G streptococcal 
bacteremia 
emm types  No. of isolates  
stG485.0  10 
stG840.0  7 
stG6.1  7 
stG166b.0  6 
stG4222.0  5 
stG10.0  3 
stG5420.0  3 
stC74a.0  3 
stG245.0  3 
stG480.0  3 
stC36.0  2 
stG6792.0
a  2 
stG6.0  1 
stG507.1
a  1 
aNew emm types. 
Figure 1. Trends in β-hemolytic streptococcal bacteremia at the
Hadassah Medical Center.the same years as our study (9), the yearly incidence of
GGS bacteremia did not increase. The dissimilarity in our
two groups may be attributable to the differences in ages of
the patients and the proportion of men. In addition, the
other hospital is a community hospital with a large geri-
atric department, without neurosurgery or bone-marrow
and solid organ transplants.
A noteworthy finding in our series was the high fre-
quency of recurrent GGS bacteremia. We identified six
patients with bacteremia, all of whom had recurrent cel-
lulitis. Five had lymphatic drainage abnormalities. Two
patients had recurrent bacteremia attributable to the same
emm type (stG840, patients 1 and 2, Table 3). PFGE results
indicated that within each patient the isolates recovered at
different time points were clonal (Figure 2) but that the
two pairs of stG840 isolates had differing PFGE patterns,
which suggests that they were different clonal types. 
Since two of the patients with recurrent bacteremia had
an infection by the same clone, these infections may have
been relapses. Recurrence of bacteremia suggests that the
initial infection may not provide protective immunity. The
question of protective immunity to this bacterium is
addressed by Bisno et al. in a murine model of recurrent
GGS cellulitis (27). Despite recurrent skin challenge with
GGS, the lesion did not decrease in severity, size, or time
to heal. Bisno et al. found that, despite the development of
demonstrable humoral immune response to M protein,
acquired protective immunity did not occur. Possibly GGS
downregulates M protein in vivo, thus allowing it to evade
these specific antibodies. Immediately initiating antibiotic
therapy for the first GGS infection might contribute to the
low level of immunity, as has been demonstrated in cases
of recurrent GAS tonsillitis (28).
Cellulitis can recur in extremities or other sites where
venous and lymphatic circulation has been compromised
by processes such as malignancy, lymph node dissection,
prior irradiation, trauma, or saphenous venectomy
(10,29,30). Nongroup A β-hemolytic streptococci have
been implicated as a major cause of cellulitis in the setting
of circulatory compromise (31,32). Focusing on the 48
patients with cellulitis, we found that recurrent cellulitis
with bacteremia was 14.1 times more likely to develop in
patients with lymphatic drainage abnormalities when com-
pared to patients without such abnormalities. Our report is
the first to describe the phenomenon of recurrent GGS cel-
lulitis associated with bacteremia in patients with lymphat-
ic abnormalities. Recurrent GGS bacteremia seems to be
more common than recurrent GAS bacteremia. In our
study of 90 patients with GAS bacteremia (33) who were
admitted to the Hadassah Medical Center during a 6-year
period, none had a recurrence compared to 6 of 84 patients
in this study (p < 0.013). Our patient with four recurrences
of GGS bacteremia had in effect five additional episodes,
which were not included in our report. Three episodes
were cellulitis with GGS bacteremia at other hospitals, and
two episodes were severe cellulitis without proven bac-
teremia. These cases are examples of recurrence of GGS
infection in a manner not known to occur with GAS. A
recent report suggested that allelic variation of human
leukocyte antigen II contributes to the differences in sever-
ity of GAS infections (34). The relationship between bac-
terial factors and host mechanisms of defense in this
patient and others with recurrent bacteremia needs further
investigation.
To illuminate the unique characteristics of patients with
GGS bacteremia, we compared our group of GGS bac-
teremia patients with two groups of GAS bacteremia
patients (33,35). Sex and age of the patients with GGS bac-
teremia were similar to those with GAS bacteremia in a
retrospective study. However, when we compared patients
with GAS bacteremia from our hospital participating in a
nationwide prospective, population-based study, GGS
patients were older and more likely to be men than the
GAS patients (35). Thus, the characteristics of the GGS
patients may reflect institutional and selection bias attrib-
utable to different study methods and may not be a true
tendency for older patients.
Serologic M typing was developed years ago for GAS
typing, but it has also been used for GGS (36). M protein
encoded by emm is a virulence factor of GGS similar to the
GAS surface protein (20). emm typing for both GAS and
GGS is based on the heterogeneity of the 5′ ends of the
gene, which give rise to different sequence types. More
than 120 emm types are recognized for GAS, and approxi-
mately 40 types of GGS and group C Streptococcus (GCS)
have been identified (http://www.cdc.gov/ncidod/
biotech/strep/emmtypes.htm). Despite the similarities
between GAS and GGS, Geyer and Schmidt (37) found
that in GCS and GGS, two types of arrangements in the
emm region differ significantly from the known types of
mga region in GAS. The conclusion was that Mgc is relat-
ed to Mga proteins of various types of GAS but forms a
distinct cluster. 
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Figure 2. Dendrogram of pulsed-field gel electrophoresis analysis
of isolates from patients with recurrent bacteremia. “Patient” refers
to numbers from Table 3.In previous studies, Lawal et al. used serologic M typ-
ing for 103 isolates of GGS. Fifty-six isolates (54%) could
be serologically typed into eight serotypes (38). Of 128
isolates, 40 (31%) could be serotyped with six antisera
(39). The inability to type a large proportion of GGS by the
older serologic method is similar to the situation that exists
for GAS (12).
In our 56 GGS isolates available for sequence typing,
we found 13 emm types. None of our isolates were emm
nontypeable. Kalia et al. (40) emm typed 18 GGS isolates
from human infections obtained from various countries.
They found 13 emm types, the most common of which was
stG480.0 (3 of 18 isolates compared to 3 of 56 in our
study); our most common type was stG485.0 (10 of 56 iso-
lates). Thus, emm typing provides a useful tool for identi-
fying isolates when compared to traditional M typing.
Tyrrell found a correlation between clusters of GAS M
types and patient age (41). We could not find a correlation
between emm type and clinical features such as patient sex,
age, and source of infection or cellulitis location, although
our database may not be sufficiently large to draw these
correlations.
We found among our GGS isolates emm types that were
previously described for GCS (stC36.0) and for GAS
(stG245.0). Although stG245.0 was originally associated
with  S. dysgalactiae subsp. equisimilis harboring group A
antigen, it is usually associated with GGS (B. Beall,
unpub. data). Kalia et al. described a few GCS emm types,
which in our study were found in group G streptococci.
Certain types are occasionally found in both GGS and
GCS (Beall, unpub. data). The dynamics of interspecies
transfer of virulence loci between GAS, GGS, and GCS
(18,42–45), as well as potential genetic transfer or intrage-
nomic events causing interconversion of group antigen
types, remains to be resolved. Our findings that several
isolates with emm type stG840 have different PFGE pat-
terns may support the notion that isolates of GGS with the
same emm type are not of the same clone. The relationship
between GGS emm type and clone remains to be exam-
ined. In general, GAS emm typing, when restricted to the
same geographic area and time period, is indicative of
clonal type; however Beall et al, (46) demonstrated numer-
ous examples of apparently unrelated GAS strains (as
judged by independent T agglutination phenotype and
opacity factor [sof] sequence) sharing the same emm
sequence type, and, more recently, nonrelatedness between
distinct GAS strains of identical emm types has been
demonstrated through MLST (47). 
In summary, we describe 94 cases of GGS bacteremia,
observed mainly in older patients with underlying medical
conditions. The most frequent portal of entry was the skin.
The high rate of recurrence of GGS bacteremia was an
unusual and unexpected finding. Clinicians should be alert
to this phenomenon, which seems to be more common
than recurrent GAS bacteremia. We found that lymphatic
drainage disorders were a highly significant risk factor for
recurrence, and that emm type stG840.0 may have a special
role in recurring disease.
Dr. Cohen-Poradosu is an infectious diseases physician in
the Department of Clinical Microbiology and Infectious
Diseases, Hadassah-Hebrew University Medical Center. Her
clinical and research interests include streptococcal infections
and antimicrobial drug–resistance patterns.
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